|
KMID : 0369820110410050273
|
|
Jorunal of Korean Pharmaceutical Sciences
2011 Volume.41 No. 5 p.273 ~ p.278
|
|
|
Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats
|
|
Choi Dong-Hyun
Choi Jun-Shik
|
|
|
Abstract
|
|
|
? The aim of this study was to investigate the effect of efonidipine on the pharmacokinetics of warfarin after oral and intravenous administration of warfarin in rats. Warfarin was administered orally (0.2 mg/kg) or intravenously (0.05 mg/kg) without or with oral administration of efonidipine (1 or 3 mg/kg) in rats. The effect of efonidipine on the cytochrome P450 (CYP) 3A4 activity was also evaluated. Efonidipine inhibited CYP3A4 enzyme activity with 50% inhibition concentration
(IC50) of 0.08 μM. Compared to those in the oral control group (warfarin without efonidipine), the area under the plasma concentration?time curve (AUC) of warfarin was significantly greater (1 mg/kg, P<0.05; 3 mg/kg, P<0.01) by 25.9-59.0%, and the peak plasma concentration (Cmax) was significantly higher (3 mg/kg, P<0.05) by 26.2% after oral administration of warfarin with efonidipine, respectively. The total body clearance of warfarin was significantly (3 mg/kg, P<0.05) decreased by efonidifine. Consequently, the relative bioavailability of warfarin was increased by 1.26- to 1.59-fold and the absolute bioavailability of warfarin with efonidipine was significantly greater by 59.7-75.4 % compared to that in the control group (47.4%). In contrast, efonidipine had no effect on any pharmacokinetic parameters of warfarin given intravenously.
Therefore, the enhanced oral bioavailability of warfarin may be due to inhibition of CYP 3A4-mediated metabolism
in the intestine and/or liver and to reduction of total body celarance rather than renal elimination, resulting in reducing
first-pass metabolism by efonidipine.
|
|
|
KEYWORD
|
|
|
Warfarin, Efonidipine, Pharmacokinetics, Bioavailability, CYP 3A, Rats
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|